Laekna doses first subjects in Phase Ib/III breast cancer therapy trial
The trial will analyse the safety and efficacy of afuresertib plus fulvestrant combination in HR+/HER2- breast cancer patients.

The trial will analyse the safety and efficacy of afuresertib plus fulvestrant combination in HR+/HER2- breast cancer patients.
Breyanzi had a manageable safety profile without any new safety signals reported.
In the trial, a mortality rate of 37% was reported in the aviptadil arm versus 36% in the placebo arm.
The first-in-human trial will enrol nearly 80 participants to analyse WP1122 for treating Covid-19.
The HBM7008 antibody has crosslinking dependent specificity on tumours and potent immune modulation activity.
The single-arm Simon's two stage trial will enrol up to 63 MPM patients across various US centres.
The Phase III trial showed that three vaccine lots that were consecutively manufactured, elicited equivalent immune responses.
In previous trials, CoviLiv showed to stimulate strong immune responses and blocked nasal replication after a single dose.